Related Experiment Video
Updated: Dec 24, 2025
Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
Prognostic value of NT-proBNP in patients with severe COVID-19
Lei Gao1, Dan Jiang2, Xue-Song Wen1
1Department of Cardiovascular Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Insights
N-terminal pro B-type natriuretic peptide (NT-proBNP) may predict mortality in severe COVID-19 patients. High NT-proBNP levels indicate an increased risk of in-hospital death, suggesting its use as an independent risk factor.
Area of Science:
- Cardiology
- Infectious Diseases
- Critical Care Medicine
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, poses a significant global health threat.
- Cardiac injury is frequently observed in hospitalized COVID-19 patients.
- The predictive value of NT-proBNP for outcomes in severe COVID-19 was previously unknown.
Purpose of the Study:
- To investigate the association between NT-proBNP levels and in-hospital mortality in severe COVID-19 patients.
- To determine if NT-proBNP can serve as a predictive biomarker for adverse outcomes in this population.
Main Methods:
- A cohort of 54 patients with severe COVID-19 was analyzed.
- In-hospital death was defined as the primary outcome (case fatality rate).
- Medical records were used to obtain clinical information and follow-up data.
Main Results:
- The optimal NT-proBNP cutoff for predicting in-hospital death was 88.64 pg/mL (100% sensitivity, 66.67% specificity).
- Patients with NT-proBNP > 88.64 pg/mL had a significantly higher risk of death.
- NT-proBNP was independently correlated with in-hospital death after adjusting for risk factors.
Conclusions:
- NT-proBNP may serve as an independent predictor of in-hospital mortality in severe COVID-19.
- This biomarker could aid in risk stratification and management of severe COVID-19 cases.
Background:
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown.
Methods:
The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records.
Results:
The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death.
Conclusion:
NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19.
Trial Registration:
ClinicalTrials, NCT04292964. Registered 03 March 2020.
More Related Videos
Related Concept Videos
01:13Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Pneumonia III: Complications and Assessment